Strengthening the EU's
pandemic preparedness











ABOUT EVAMOBS
A novel platform to develop antivirals
EvaMobs is developing new ways to discover and evaluate protein-based antivirals. Evolvable monobodies, or “Mobs,” are central to the project’s platform.
As the research progresses, consortium partners are also designing other antiviral proteins, such as miniproteins and nanobodies.
These molecules can be tailored to have a high affinity for any type of target. In other words, this technology can be used to easily generate specific proteins that can “attack” and inactivate a particular virus.
Using state-of-the-art computational tools in combination with efficient experimental validation, EvaMobs is creating an innovative platform for the rapid development of new antiviral drugs.
A monobody (in pink) tightly bound to the
SARS-COV-2 receptor binding domain (in blue). Monobodies are one of the protein-based antiviral approaches investigated by EvaMobs.
IN A NUTSHELL
EvaMobs under 2 minutes
Curious about a quick overview of the EvaMobs project? Watch our project video!
ABOUT EVAMOBS
Our research steps
Discover antiviral
candidates
With a computational framework, millions of computer-designed antiviral proteins will be discovered, and characterised.
Production of
specific antiviral
proteins
A narrowed down selection of discovered antivirals will be produced.
Preclinical
validation
The antiviral proteins will undergo testing of the safety, efficacy and the dosage in preclinical models.
Phase 1 clinical
validation
The most promising antiviral protein will be tested for safe use in humans.
![]()
Discovery antiviral candidates
With a computational framework, millions of computer-designed antiviral proteins will be discovered, and characterised.
![]()
Production of
specific antiviral proteins
A narrowed down selection of discovered antivirals will be produced.
![]()
Preclinical
validation
The antiviral proteins will undergo testing of the safety, efficacy and the dosage in preclinical models.
![]()
Phase 1
clinical validation
The most promising antiviral protein will be tested for safe use in humans.
OUR LATEST UPDATES
News

From protein design tools to shared ideas: European Rosetta Workshop 2026
What can happen when researchers with different backgrounds take on a protein design challenge together? At this year’s European Rosetta Workshop participants explored that question hands-on, bringing computational tools, fresh perspectives and collaborative problem-solving to the table.

Catch a glimpse of our recent consortium meeting
Where do we stand now and where will be go next? Catch a glimpse of our recent consortium meeting in Madrid.

EvaMobs 3rd Consortium Meeting: From design to validation – and closer to real-world antivirals
Three years into EvaMobs, we came together once again – this time in Madrid, hosted by our partners at CNB-CSIC. Over two packed days, we shared progress, connected results across disciplines, and aligned on what comes next.
WORK WITH US
Job offers
Postdoc Position - CNB-CSIC
Three-dimensional reconstruction, using cryo-EM data, of complexes between different viral receptors and synthetic antiviral proteins
There are currently no job offers available
Postdoc Position - IMROH, Zagreb, Croatia
Initial assessment of monobodies' (Mobs) effects on human cells
TEAM
Our partners
EvaMobs is a consortium consisting of 11 European partners, coordinated by ITQB NOVA, NOVA University of Lisbon.











OUR RESULTS
Activities and Outputs
Find our communication activities, publications and other outputs.

